key: cord-0903922-u8ptvem7
authors: Sun, Roger; Achkar, Samir; Ammari, Samy; Bockel, Sophie; Gallois, Emmanuelle; Bayle, Arnaud; Battistella, Enzo; Salviat, Flore; Merad, Mansouria; Laville, Adrien; Ka, Kanta; Griscelli, Franck; Albiges, Laurence; Barlesi, Fabrice; Bossi, Alberto; Rivera, Sofia; Chargari, Cyrus; Deutsch, Eric
title: Systematic screening of COVID-19 disease based on chest CT and RT-PCR for cancer patients undergoing radiotherapy in a coronavirus French hotspot.
date: 2021-02-17
journal: Int J Radiat Oncol Biol Phys
DOI: 10.1016/j.ijrobp.2021.02.022
sha: 37fc64171ca49a18b4ba9e7f53cba5e7a73e33cc
doc_id: 903922
cord_uid: u8ptvem7

Background Cancer patients are presumed to be more vulnerable to COVID-19. We evaluated a screening strategy combining chest computed-tomography (CT) and reverse transcription polymerase chain reaction (RT-PCR) for patients treated with radiotherapy (RT) in our cancer center located in a COVID-19 French hotspot during the first wave of the pandemic. Methods Chest CT images were proposed during the radiotherapy CT simulation. Images were reviewed by an expert radiologist according to the CO-RADS classification. Nasal swabs with RT PCR assay were initially proposed in case of suspicious imaging or clinical context and were eventually integrated into the systematic screening. A dedicated radiotherapy workflow was proposed for COVID-19 patients to limit the risk of contamination. Results From March 18, 2020 to May 1, 2020, 480 patients were screened by chest CT, with 313 patients having both chest CT and RT-PCR (65%). Cumulative incidence of COVID-19 was 5.4%, 95%CI [3.6, 7.8] (26 patients out of 480). Diagnosis of COVID-19 was made before RT for 22 patients (84.6%) and during RT for 4 patients (15.3%). Chest CT directly aided the diagnosis of 7 cases for whom the initial RT-PCR was negative or not feasible; out of a total of 480 patients (1.5%) and 517 chest CT acquisition. Four patients with COVID-19 at the time of the chest CT screening had a false negative CT. Sensitivity and specificity of chest CT screening in patients with both RT-PCR and chest CT testing were estimated to be 0.82, 95% CI [0.60, 0.95] and 0.98, 95% CI [0.96, 0.99] respectively.Adaptation of the radiotherapy treatment was made for all the patients with seven postponed treatments (median=5 days, IQR [1.5, 14.8]). Conclusion The benefit of systematic use of chest CT screening during CT simulation for patients undergoing radiotherapy during the COVID-19 pandemic seemed limited.

Adaptation of the radiotherapy treatment was made for all the patients with seven postponed 23 treatments (median=5 days, IQR [1.5, 14.8 

Conclusion 25

The benefit of systematic use of chest CT screening during CT simulation for patients 26 undergoing radiotherapy during the COVID-19 pandemic seemed limited. Management of cancer patients during this health crisis has been particularly challenging with 41 many uncertainties regarding the risk of severity of COVID-19 for patients undergoing anti-42 cancer treatment and affected by COVID-19 (6-11). For patients undergoing radiation 43 therapy, chest screening can be performed without modifying the patient workflow, as the 44 treatment planning requires a CT simulation for each patient. Therefore, screening based on 45 chest CT and RT-PCR was implemented to control and mitigate the risk of COVID-19 46 spreading within our radiation oncology department, located in a coronavirus hotspot. This 47 study aimed to assess the feasibility of this COVID-19 screening procedure and to evaluate 48 the performance of chest CT as a screening tool in our radiotherapy department in the context 49 of limited availability of RT-PCR tests at the time of the first France lockdown. Study Design and screening strategy  53   Between March 18, 2020 and May 10, 2020, a screening strategy for COVID-19 based on a  54 chest CT acquisition was proposed to all patients undergoing a CT simulation when feasible 55 by our radiation therapy department. We performed a unicenter retrospective observational 56 study including all patients with cancer (solid tumors or hematological malignancies) who 57 underwent a chest CT screening during CT simulation. The use of RT-PCR in this screening 58 strategy evolved over time, according to the availability of testing resources. Nasopharyngeal 59 swabs for RT-PCR testing were firstly limited to symptomatic patients and asymptomatic 60 patients with suspicious chest CT images. In early April, RT-PCR testing was extended to all 61 the patients undergoing chemoradiotherapy. As of April 20, 2020, systematic COVID-19 RT-62

PCRs were performed before the first RT session since large implementation of virus testing 63 in local laboratories were available. Patients could also have benefited from RT-PCR 64 screening before the start of radiotherapy in our center, i.e. before surgery, or chemotherapy, 65 or in the context of an ongoing observational study conducted in our center. Breath-hold chest CT scans were obtained using a 16-row multi-detector scanner (Siemens 76 Sensation 16, Erlangen, Germany) with the following parameters: 120 kVp, 150 mA, 1.7 77 collimation and 1.5:1 pitch. Images were reconstructed with a reconstruction matrix of 78 512X512, a slice thickness of 1mm, and a BI57 (lung parenchyma) kernel (Siemens 79 Healthineers). The width and level of the pulmonary window were set as 1500/-500. Free-80 breathing acquisition could have been carried out for some patients with deterioration of 81 health conditions. Chest acquisition was not carried out when CT simulation was obtained in 82 feet first orientation (i.e. lower limbs irradiation) to avoid additional repositioning. 83

All chest CT images were analyzed by an 8-year experienced radiologist without access to 84 clinical or laboratory findings, within 48h of image acquisition. COVID-19 associated CT 85 imaging features were described in accordance with ACR recommendations, (12), and 86 included ground glass opacity, consolidation, interlobular septal thickening or "crazy paving", 87 subpleural line, lymph node enlargement, pleural effusion, and pericardial effusion (13). The Clinically positive COVID-19 cases were defined as patients with suspicious symptoms and 108 chest CT images but negative RT-PCR. 109

A direct benefit of chest CT screening was defined by the diagnosis of confirmed or clinically 110 positive COVID-19, in patients who were not known to be actually or recently infected, or 111 who were not specifically tested for COVID-19 (RT-PCR and/or diagnostic chest CT) due to 112 acute symptoms, and for whom a concomitant RT-PCR testing was not feasible or considered 113 as false negative. 114

Clinically positive COVID-19 cases were considered as a gold standard to assess the 116 performance of RT-PCR testing, and chest CT for the diagnosis of COVID-19. Accuracy of 117 chest CT screening for the diagnosis of COVID-19 was estimated using data of patients 118 having both RT-PCR testing and chest CT. This limited bias linked to the risk of 119 overestimation of patients considered negative by scan, and who had not been confirmed by 120 PCR. Results of sensitivity and specificity of chest CT at the time of RT screening are 121

presented. 122

The analysis of RT-PCR accuracy for the diagnosis of COVID-19 included all the serial RT-123 PCR results available in this cohort. 124

Analyses were performed using R software version 3.6.0 (https://www.r-project.org/) (14). 125

Comparisons of demographic variables and clinical variables between patient groups were 126 performed using Fisher test for categorical variables and Wilcoxon signed-rank test or 127

Kruskal-Wallis test for continuous variables in Table 1 and Table S5 (Table 2A and Table S3) . 165

To note, two other patients developed a COVID-19 infection after the start of radiotherapy, 166 leading to a total of 26 COVID-19 patients during this period, with a cumulative incidence of 167 5.4% (95%CI [3.6, 7.8]) (Figure 2) . 168

The details of RT-PCR tests carried out in COVID-19 patients are summarized in Table 2B  169 and (Table 3) . 172

Although 11 COVID-19 patients detected by chest CT screening were asymptomatic at the 173 time of the screening , it was estimated that chest CT screening played a central role in the 174 diagnosis of only 7 out of the 480 screened patients (1.5%) ( Table 3 and Table S4 ). Among 175 these 7 patients, 5 patients with initially negative RT-PCR results presented suspicious chest 176 CT images (CO-RADS ≥ 4) on screening, prompting repeated nasopharyngeal swabs that 177 finally confirmed the carriage of SARS-CoV 2. One patient refused the nasopharyngeal 178 sample due to palliative status and health condition deterioration, while another patient had a 179 negative RT-PCR test, however both had suspicious images and compatible symptoms (Table  180 3). They were considered clinically positive COVID-19 patients and managed the same way 181 as RT-PCR positive patients. 182

Diagnosis of COVID-19 allowed treatment adaptation for all the COVID-19 patients (Table  183   S5 In this study, we reported the results of an active screening combining chest-CT and RT-PCR 190 of patients undergoing radiotherapy in a tertiary cancer center in Ile-de-France at the peak of 191 the first wave of the COVID-19 pandemic. 192

While several authors have shown that chest CT may have higher sensibility than RT-PCR for 193 COVID-19 diagnosis (15), its role for mass screening was highly debated due to radiation 194 exposure and a possible low predictive value due to low specificity (16), and guidelines did 195 not recommend chest CT as a screening tool in the overall population (17). However, the 196 downside of such exams appeared to be low for cancer patients undergoing radiotherapy and 197 could have seemed to be interesting when access to RT-PCR tests were limited (18). CT 198 simulation is needed in radiotherapy for treatment planning, and while free-breathing images 199 are usually performed, breath-hold chest acquisition can be easily added without modifying 200 the patient workflow. Moreover, the radiation exposure might be considered as negligible in 201 regards to radiotherapy, even for extra-thoracic treatments. Indeed, it has been shown that 202 0.05%-0.7% of the prescribed dose is still delivered at 30 cm from the irradiated field. 203 Namely, a pelvic treatment of 45 Gy may deliver around 25-315 mGy to the chest, which is 204 equivalent to 3-40 chest CT (19). 205

Although we confirmed a good sensitivity and reasonable specificity of chest CT for the 206 diagnosis of COVID-19, the direct benefit of chest CT screening seemed limited in our study. 207

Indeed, most cases detected by chest CT screening reported a history of symptoms or close 208 contact with COVID-19 positive persons, and most of them could be detected by serial RT-209

We acknowledge that this study had some limitations. Firstly, the screening procedure, and in 211 particular the use of PCR, has evolved over time, depending on the availability of this test, 212 bringing some heterogeneity in the management of patients. However, screening results of all 213 the patients were discussed prospectively by the same team, which helped to ensure 214 homogeneous decisions regarding access to RT-PCR tests. Secondly, the number of COVID-215 19 patients detected in our cohort was relatively low, which might have brought uncertainties 216 in the estimation of chest CT performance, therefore results should be interpreted with 217 caution. This study was carried out in the context of the pandemic peak of COVID-19 in 218 

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of 239 Infected Patients

CO-RADS -A categorical CT 241 assessment scheme for patients with suspected COVID-19: definition and evaluation

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Evaluating the accuracy of different respiratory specimens in the 246 laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 248 2019 (COVID-19) in China: A Report of 1014 Cases

Cancer patients in SARS-CoV-2 infection: a nationwide analysis 250 in China

Do patients with cancer have a poorer prognosis of 252 COVID-19? An experience in

COVID-19 mortality in patients with cancer on 254 chemotherapy or other anticancer treatments: a prospective cohort study

High mortality rate in cancer patients with symptoms of 257 COVID-19 with or without detectable SARS-COV-2 on RT-PCR

Cancer patients and research during COVID-19 pandemic: A 259 systematic review of current evidence

Determinants of the outcomes of patients with cancer infected 261 with SARS-CoV-2: results from the Gustave Roussy cohort

Radiological Society of North America Expert Consensus 263 Statement on Reporting Chest CT Findings Related to COVID-19

Thoracic Radiology, the American College of Radiology, and RSNA. Radiology: Cardiothoracic 265 Imaging

Fleischner Society: Glossary of Terms for 267

R: A Language and Environment for Statistical Computing

Efficacy of Chest CT for COVID-19 Pneumonia in France

Diagnostic Performance of CT and Reverse Transcriptase-Polymerase 273

Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis

American College of Radiology. ACR Recommendations for the use of Chest Radiography and 275

Computed Tomography (CT) for Suspected COVID-19 Infection

Chest-Radiography-and-CT-for-Suspected-COVID19-278 Infection#:~:text=The%20Centers%20for%20Disease%20Control

Optimization of Patient Management During the COVID-19

Pandemic: Chest CT Scan and PCR as Gatekeepers of the Radiation Therapy Workflow

A multi-plane source model for out-of-field head scatter 283 dose calculations in external beam photon therapy

Priority COVID-19 Vaccination for Patients with Cancer 285 while Vaccine Supply Is Limited. Cancer Discov

Abbreviations. Y: years RT: radiotherapy, BT: brachytherapy, pt: patient, N: number, GI: gastro-intestinal, RT-PCR: reverse transcription polymerase chain reaction

Before RT: n=6 • Symptoms during the screening

• Positive PCR at the time of CT simulation: n=5 • Screening CT CORADS 4-5: n=5/5

• 1 pt had false negative PCR initially • PCR turned negative at the time of CT simulation: n=1 (Screening CT CORADS 2) CT CORADS 4-5: n=1 COVID-19 developed during RT: n=2 • Initial screening CT negative • Symptoms during RT, diagnostic CT CORADS 4, but negative PCR: n=1* • Systematic on-treatment PCR positive

The authors would like to thank the patients, their families and all investigators and caregivers involved in the COVID-19 pandemic management at Gustave Roussy. We would like to thank especially Najma Douir, Gaëlle Mevel, Khadi Diop, Simon Corbin, Frederik Hubert, Gianfranco Brusadin, and all the radiotherapists. We would like to thank Zaarour Tina Marie for the english editing.

J o u r n a l P r e -p r o o f Tables 2A. Contingency table of chest CT screening CO-RADS score according to COVID-19 status for patients with both chest-CT and RT-PCR available at the time of the COVID-19 diagnosis. The highest CO-RADS score for each patient were kept in case of multiple chest CT.